Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921878 | 1.00 | FLT3 (0.52) | FLT3PDGFRBKITMAP4K4CNR1 | |
| SCHEMBL4960681 | 0.87 | MAP4K4 (0.48) | MAP4K4CNR1CNR2KDRCKS1B | |
| SCHEMBL16142422 | 0.86 | MAP4K4 (0.48) | MAP4K4CNR1CNR2KDRCKS1B | |
| SCHEMBL20612718 | 0.82 | MAP4K4 (0.52) | MAP4K4CNR1CNR2KDRCKS1B | |
| SCHEMBL4962116 | 0.81 | MAP4K4 (0.54) | MAP4K4CNR1CNR2CKS1BSKP1 | |
| SCHEMBL4961362 | 0.79 | FLT3 (0.72) | FLT3PDGFRBKITKDR | |
| SCHEMBL4961375 | 0.79 | FLT3 (0.72) | FLT3PDGFRBKITKDR | |
| SCHEMBL4963771 | 0.78 | FLT3 (0.73) | FLT3PDGFRBKITKDR | |
| SCHEMBL4963757 | 0.78 | FLT3 (0.63) | FLT3PDGFRBKITKDR | |
| SCHEMBL4963769 | 0.78 | FLT3 (0.63) | FLT3PDGFRBKITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281764-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060281700-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281764-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | FLT3, KIT, TYMP | FLT3 1/4885PDGFRB 29/4885KIT 2/4885 |
| US-20060281700-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | FLT3, TYMP, PHKG1 | FLT3 1/4885PDGFRB 143/4885KIT 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.